Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Culmerciclib + Endocrine Therapy in HR+/HER2- Early Breast Cancer
NCT07796880Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of culmerciclib in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Rate of participants achieving Residual Cancer Burden grade 0 or 1. Started Sep 2026; status: recruiting.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07796880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796880.